Phase III trial of Italian HIV vaccine to begin in October
BY Advocate.com Editors
August 23 2002 12:00 AM ET
Phase III testing of an experimental HIV vaccine developed by researchers at Italy's University of Milan is scheduled to begin in October, with results due in about two years, Reuters Health reports. The vaccine uses an altered form of tat, an HIV protein, to prompt an immune system response that can keep HIV replication rates under control in people already infected with the virus. It is not designed to prevent infection. The Phase III trial will involve 120 HIV-positive adults and 40 HIV-negative adults.
"So far, the results are very encouraging," said Pier Mannuci, director of the Hemophilia and Thrombosis Center at the university. "We can claim that all patients enrolled in the [previous] trials are in good condition."
The trial will mark only the second Phase III trial--the final step before submitting a compound to regulators for marketing approval--for an experimental HIV vaccine. VaxGen's AIDSVAX is the only other experimental HIV vaccine to be in final-stage testing.
Sign Up For Email Updates
- Crime Gay Man Gunned Down in NYC Street, Dies UPDATED: May 18 2013 7:24 PM
- Youth Florida Teen Arrested, Expelled for Same-Sex Relationship May 18 2013 6:58 PM
- Media Legendary Gay Gossip Columnist Michael Musto Responds to Being Laid Off May 18 2013 3:21 PM
- Marriage Equality Vive la France! Hollande Signs Marriage Equality Bill May 18 2013 12:20 PM
- Photography Photos: Cuba Libre May 18 2013 5:29 AM
- Television These 20 Sexy Pics of Stephen Amell Will Hit Your Bullseye May 17 2013 9:00 PM
- Politics Portugal Approves Adoption Rights for Same-Sex Spouses May 17 2013 8:32 PM